Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label, Single-Arm Trial Using KEYTRUDA (Pembrolizumab) as Initial Systemic Therapy in the Treatment of Advanced Mycosis Fungoides

NCT03695471 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03695471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03695471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label, Single-Arm Trial Using KEYTRUDA (Pembrolizumab) as Initial Systemic Therapy in the Treatment of Advanced Mycosis Fungoides
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
February 4, 2020
Completion date
October 8, 2024
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mycosis fungoides, sezary syndrome, stage ib mycosis fungoides and sezary syndrome ajcc v8, stage ii mycosis fungoides and sezary syndrome ajcc v8, stage iia mycosis fungoides and sezary syndrome ajcc v8, stage iib mycosis fungoides and sezary syndrome ajcc v8, stage iii mycosis fungoides and sezary syndrome ajcc v8, stage iiia mycosis fungoides and sezary syndrome ajcc v8, stage iiib mycosis fungoides and sezary syndrome ajcc v8, stage iv mycosis fungoides and sezary syndrome ajcc v8, stage iva1 mycosis fungoides and sezary syndrome ajcc v8, stage iva2 mycosis fungoides and sezary syndrome ajcc v8, stage ivb mycosis fungoides and sezary syndrome ajcc v8